Dicerna Pharmaceuticals has dosed the first subject in a Phase I clinical trial investigating DCR-HBVS for the treatment of adults with chronic hepatitis B virus (HBV) infection.

DCR-HBVS is an experimental GalXCTM-based therapy designed for use in the treatment of HBV infection.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The DCR-HBVS-101 trial principal investigator Edward Gane said: “RNAi-based therapy has the potential to change the treatment paradigm for patients with chronic HBV infection.

“By silencing not only the S antigen but also other viral genes through a powerful and long-acting mechanism, RNAi-based therapy could tip the balance toward allowing the patient’s own immune system to mount an effective immune response.

“This approach could help eradicate HBV and remove the need for life-long therapy.”

“RNAi-based therapy has the potential to change the treatment paradigm for patients with chronic HBV infection.”

The randomised, placebo-controlled trial intends to analyse the safety and tolerability of DCR-HBVS in normal healthy volunteers (NHVs) and in patients with non-cirrhotic chronic HBV.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It comprises three groups, with Group A contains 30 NHVs who will receive a single ascending-dose of DCR-HBVS and will be followed for four weeks.

Group B features a single-dose phase and will include eight patients with HBV who are naïve to nucleoside analog therapy.

Patients in Group B are expected to be followed for at least 12 weeks, with dosing scheduled to begin in the third quarter of this year.

Group C of the DCR-HBVS-101 trial includes a multiple ascending-dose phase and intends to enrol 18 patients with HBV previously treated with nucleoside analogs with a follow-up period of 24 weeks or more.

Dicerna plans to start dosing Group C patients in the second quarter of this year.

The trial’s secondary endpoints are the pharmacokinetic (PK) profile of DCR-HBVS, and evaluation of preliminary pharmacodynamics (PD) and antiviral efficacy on plasma levels of hepatitis B surface antigen (HBsAg) and HBV in blood.

Proof-of-concept data from the trial is expected to be available in the second half of this year.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact